Delivery Order SPE2DR25D2206-SPE2DR26F9AY5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,496.42. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is scheduled for completion by October 24, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Otezla 30 mg tablets (60-count) valued at $10,291.31 under a firm fixed-price contract. This competitive award, which carries no set-aside designation, represents a direct purchase order for this pharmaceutical product to support federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $29,588.62. This firm fixed-price delivery order, which is expected to conclude by August 15, 2025, represents a competitively awarded, non-set-aside contract with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award demonstrates the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $26,675.43 to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Otezla 30 mg tablets (60-count packaging). The contract represents a firm fixed price delivery order with an ultimate completion date of December 2, 2025, and was competitively awarded without any set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,940.38. This firm fixed-price delivery order, which is not set-aside and represents the culmination of competitive procurement, is scheduled for completion by August 7, 2025. The award supports the federal medical supply chain, with performance occurring at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $13,807.38. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical vendor. The order is scheduled for completion by September 9, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,976.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $4,438.86. This is a firm fixed price delivery order with an ultimate completion date of September 30, 2025, and no set-aside designation was used in the competitive award process. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Otezla 30 mg tablets in a quantity of 60 units, with a ceiling value of $8,658.32. This is a firm fixed-price delivery order with no set-aside designation, utilizing open competitive procurement. The contract is scheduled for ultimate completion by November 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $19,860.97 delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 26, 2025, with completion expected by June 27, 2025. This firm fixed-price contract represents a non-competitive set-aside and reflects AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The order is being performed at the contractor's corporate office location in...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9AY5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $9,461.61. This firm fixed-price delivery order, which is not set-aside, is expected to be completed by November 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier within the federal medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that enables the company to supply pharmaceuticals and medical commodities to support military healthcare systems globally. AmerisourceBergen's competitively awarded contract portfolio with the Defense Logistics Agency demonstrates the company's established capability to meet federal pharmaceutical procurement requirements across diverse therapeutic domains, including specialty medications, brand-name and generic drugs, and vaccines.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 11/10/25 |